|
Synonyms: DOV 216,419 | DOV-216419 | EB-1020 | Simtriyo®
centanafadine is an approved drug
Compound class:
Synthetic organic
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI. (2012)
Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse, 66 (6): 522-32. [PMID:22298359] |
|
2. Ji J, Hu Z, Zheng F, Zheng J, Cheng J, Zayniddin N, Abduahadi S, Wang G, Gong X, Pan L et al.. (2025)
D-morphinan analogs with favorable pharmacokinetic profiles as dual-acting antidepressants. Eur J Med Chem, 287: 117349. [PMID:39952098] |
|
3. Kang C. (2026)
Centanafadine: First Approval. Drugs, [Epub ahead of print]. [PMID:42925388] |
|
4. Li Y, Meng Y, Li N, Zhao J, Li R, Bai Q, Wang G, Zhao Y. (2025)
Structural basis for pharmacotherapeutic action of triple reuptake inhibitors. Nat Commun, 17 (1): 61. [PMID:41392177] |
|
5. Nageye F, Cortese S. (2019)
Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD. Expert Rev Neurother, 19 (7): 707-717. [PMID:31167583] |
|
6. Veronesi GF, Gabellone A, Tomlinson A, Solmi M, Correll CU, Cortese S. (2024)
Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults. Neurosci Biobehav Rev, 163: 105774. [PMID:38914177] |
|
7. Wilens TE, Oberdhan D, Jin N, Skubiak T, Childress AC, van Stralen J, Ward CL. (2026)
Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol, 36 (5): 266-277. [PMID:41958186] |